Keven Macareno is a Senior Research Associate at Lime Therapeutics with over five years of experience in molecular biology, gene editing, and preclinical therapeutic development. Before joining Lime, he contributed to the development of TALEN® gene-editing technologies at Cellectis and supported lentiviral vector production along with cell engineering programs at Gentibio. His research focuses on applying molecular biology expertise to develop and optimize technologies that enable next-generation cell therapies. He earned a B.S. in Health: Science, Society and Policy with a biotechnology focus from Brandeis University. Keven is passionate about advancing allogeneic cell therapy platforms to address diverse medical needs and bring transformative treatments to patients.